Abstract 2930
Background
Early diagnosis of cancer is an important factor in increasing success in treatment. Nursing and nursing students who take care of the patient in clinical area practices can have a major impact on the disease by providing early diagnosis of the cancer. Limited study was explored awareness of nursing student about the warning signs of cancer.
Methods
A cross-sectional descriptive study was conducted from January-March 2019. The sample size was measured Raosoft online calculator programme. A total of 460 nursing students participated in this study. Data was was obtained from nursing student via self-report using the data collection form developed by researchers based on literature. The Chi-square test was performed to evaluate differences among groups.
Results
The mean age of the nursing students was 20.05 ± 2.04; most of the students were female (82.6%). The knowledge level of warning signs of cancer of the students who were female was significantly higher than male students; as following; the symptoms of change in bowel or bladder habits (p = 0.001); unusual bleeding or discharge (p = 0.01); thickening or lump in the breast or elsewhere (p = 0.004); indigestion or difficulty in swallowing (p = 0.002); obvious change in a wart or mole (p = 0.003); nagging cough or hoarseness (p = 0.04). The knowledge level of warning signs of cancer of the students who took ’Internal Medicine Nursing’ lesson was significantly higher than others; as following; the symptoms of change in bowel or bladder habits (p = 0.000); a sore that doesn’t heal (p = 0.002); unusual bleeding or discharge (p = 0.03); indigestion or difficulty in swallowing (p = 0.000); obvious change in a wart or mole (p = 0.000); nagging cough or hoarseness (p = 0.001).
Conclusions
It is thought that the majority of nursing students know warning signs of the cancer and are associated with the education given in ’Internal Medicine Nursing’. It is recommended that nursing students take part in early diagnosis and screening programs in cancer. Female nursing students more aware than male students. Because; cancer prevention campaigns have focused breast and cervical cancer which involves only females. Cancer prevention campaigns should be organized for lung, prostate and colorectal cancer which are more common in men.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2600 - Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the Phase III IMvigor211 study
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3598 - Three-Year Follow-Up From the Phase 3 KEYNOTE-045 Trial: Pembrolizumab (Pembro) Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (UC)
Presenter: Andrea Necchi
Session: Poster Display session 3
Resources:
Abstract
2382 - First Report of Efficacy and Safety From a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma (UC) in Asian Patients
Presenter: Dingwei Ye
Session: Poster Display session 3
Resources:
Abstract
2388 - Quality of Life of Metastatic Urothelial Cancer (mUC) Patients Treated with Enfortumab Vedotin (EV) Following Platinum-Containing Chemotherapy and a Checkpoint Inhibitor (CPI): Data from EV-201 Cohort 1
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
3748 - Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
1126 - Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors
Presenter: Rafael Morales Barrera
Session: Poster Display session 3
Resources:
Abstract
3693 - Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer
Presenter: Justin Matulay
Session: Poster Display session 3
Resources:
Abstract
4840 - Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
1221 - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Presenter: Jean Hoffman-censits
Session: Poster Display session 3
Resources:
Abstract
1715 - National Small Cell Bladder Cancer Audit: Results from 26 UK institutions
Presenter: Caroline Chau
Session: Poster Display session 3
Resources:
Abstract